Open AccessPharmacogenetics of antiviral agents for the treatment of COVID-19
Author(s) -
И. И. Темирбулатов,
А. V. Kryukov,
D. А. Sychev
Publication year - 2022
Publication title -
farmakogenetika i farmakogenomika
Language(s) - English
Resource type - Journals
eISSN - 2686-8849
pISSN - 2588-0527
DOI - 10.37489/2588-0527-2021-1-38-41
Subject(s) - pharmacogenetics , favipiravir , covid-19 , medicine , pharmacology , pharmacokinetics , virology , biology , genotype , infectious disease (medical specialty) , genetics , gene , disease , outbreak
Presented a literature review on the possible influence of pharmacogenetic markers on the efficacy and safety of COVID-19 therapy. Clinical studies of remdesivir and favipiravir are reviewed. Potential pharmacogenetic markers are described based on the available data on the pharmacokinetics of the drugs. We separately described the effect of the infectious-inflammatory process on the expression of cytochrome family enzymes.